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Abstract 
 
Scope 
Polycystic Ovary Syndrome (PCOS) is underpinned by IR. In PCOS, the relationships 
between vitamin D, adiposity and IR are unclear. We aim to explore these relationships in 
lean and overweight women with PCOS.  
 
Methods and results 
This is a cross-sectional study conducted in a tertiary medical centre. Participants included 42 
women with PCOS and 34 controls without PCOS. Vitamin D and metabolic markers were 
measured. Detailed body composition and gold standard hyperinsulinaemic euglycaemic 
clamps were performed. The main outcome measures were plasma levels of vitamin D, 
adiposity measures and glucose infusion rate (GIR).  
 
Vitamin D levels were lower in overweight women with PCOS compared with overweight 
controls (31.6 and 46.1 nmol/L respectively, p=0.01). Vitamin D was not associated with IR 
after adjustment for confounders; however, there was a significant interaction between PCOS 
and % body fat. Further analysis by PCOS status revealed that vitamin D was associated with 
IR in the PCOS group (β coefficient 2.1, 95% CI 0.2–4.0, p=0.03), but not in the non-PCOS 
group.  
 
Conclusion 
Vitamin D is associated with IR in women with PCOS, but not in controls. Large intervention 
studies are needed to determine if vitamin D supplementation can improve IR in PCOS.  
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Introduction 
 
Vitamin D is a fat soluble vitamin that is involved in bone metabolism and calcium 
homeostasis (1). It has been emerging over recent years that vitamin D may have a role in 
disorders outside the skeletal system including immune disorders, diabetes, hypertension, 
cardiovascular disease, infectious diseases and cancer (2-4). Vitamin D deficiency is very 
prevalent worldwide, as people adopt sedentary indoor lifestyles and use sunscreen and 
protective clothing to reduce skin cancer risk (5). Despite our sunny climate, vitamin D 
deficiency is also common in Australia. The AusDiab Study reported vitamin D deficiency 
(vitamin D <50 nmol/L) in 50% of women and 31% of men living at latitudes >35 degrees 
south – which includes Melbourne, the location of the current study (6). Low vitamin D 
levels have been found in type 2 diabetes mellitus (T2DM) and correlate with obesity, 
pancreatic beta cell dysfunction and insulin resistance (IR) and risk of developing T2DM (7-
10). Supplementation of vitamin D has been shown to improve IR (11) and prevent T2DM 
(9).  
 
Polycystic ovary syndrome (PCOS) is a common disorder that affects 9-21% of reproductive-
aged women (12), depending on the population studied and the diagnostic criteria applied. 
PCOS diagnosis is based on menstrual disturbance (oligo or amenorrhoea), clinical or 
biochemical hyperandrogenism and polycystic ovaries on ultrasound (13). IR plays a central 
pathophysiological role in the majority of women with PCOS (14) and underpins significant 
metabolic complications in PCOS including dyslipidaemia, dysglycaemia and 
hyperandrogenism (15). IR in PCOS is both independent of and exacerbated by obesity (16). 
Approximately 60% of Australian women with PCOS are overweight or obese and women 
with PCOS may also have a relatively greater central adiposity distribution compared to 
controls with equivalent BMI (16).  
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Several recent studies have explored the association of vitamin D with IR and metabolic 
features in PCOS (17-19); however these studies used indirect measures of IR such as oral 
glucose tolerance tests, Homeostasis Model Assessment (HOMA) and Quantitative Insulin 
Sensitivity Check Index (QUICKI).  There has only been one study to date examining the 
relationship between vitamin D and IR in PCOS using hyperinsulinaemic euglycaemic 
clamps (gold standard); however this study did not have a control population. This study 
suggested that vitamin D levels in PCOS are primarily related to adiposity (20). A recent 
randomised controlled trial shows that supplementation with vitamin D improved IR, 
suggesting that vitamin D might have a protective role in the development of IR in women 
with PCOS (21). Women with PCOS often demonstrate clustering of cardiovascular risk 
factors and may have an increased risk of cardiovascular disease (22). It has been suggested 
that vitamin D may have a protective effect on some cardiovascular risk factors (23).  
To this end, we measured adiposity, IR (gold standard measures), lipid profile and blood 
pressure in lean and overweight women with PCOS and without PCOS to further explore 
relationships between vitamin D, metabolic and cardiovascular risk factors in PCOS. The 
current study adds to existing literature with the inclusion of both women with PCOS and 
controls, including lean and overweight subjects and the use of clamp studies and detailed 
body composition measures. We hypothesized that obese women will have lower vitamin D 
compared to lean women and women with PCOS will have lower vitamin D levels compared 
to women without PCOS. In addition, we hypothesized that vitamin D will be further lowered 
by presence of cardiovascular risk factors. 
 
Methods and methods 
 
Subjects 
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Women were recruited from community advertisements (16). This vitamin D study is part of 
a PCOS study investigating insulin resistance in PCOS (16). 76 women were eligible and had 
completed 3 months run-in phase as previously described (16). The women were categorised 
according to PCOS status and BMI. Women were allocated into two BMI categories (lean 
and overweight) based on the threshold BMI of 27kg.m
-2
, as an a priori decision, as this is 
the inflexion point in the relationship between BMI and IR (16). We analysed baseline data 
from 76 women (n=22 lean women and n=20 overweight women with PCOS and n=19 lean 
and n=15 overweight control women without PCOS).  
 
As previously described, diagnosis of PCOS was undertaken by expert endocrinologists 
based on Rotterdam criteria with two of a) irregular menstrual cycles (<21 or >35 days), b) 
clinical (hirsutism, acne) or biochemical (elevation of at least one circulating ovarian 
androgen) hyperandrogenism and c) PCO on ultrasound (24). Hyperprolactinemia, thyroid 
dysfunction and specific adrenal disorders were excluded clinically and where indicated, 
biochemically. All women without PCOS had regular menses and no evidence of clinical or 
biochemical hyperandrogenism. Exclusion criteria were smoking, diabetes, recent weight 
change of 5 kilograms or more in the previous six months, actively trying to lose weight and 
pregnancy.  
 
The Southern Health Research Advisory and Ethics Committee approved the study and all 
participants gave written informed consent.  
Study Design 
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At screening (3 months prior to baseline), standard diet and lifestyle advice were delivered 
[Heart Foundation of Australia recommendations (www.heartfoundation.org.au)] as 
previously described (25). Medications affecting end-points including insulin sensitisers, 
anti-androgens and hormonal contraceptives were ceased for 3 months. Data were collected 
following this 3 month run-in phase and was collected in the follicular phase of the menstrual 
cycle wherever feasible.  
 
Anthropometric Measurements  
Participants were weighed lightly clothed without shoes (Tanita TBF310, Tokyo, Japan) 
followed by height measurements (Stadiometer Holtain, Wales, UK) for the calculation of 
BMI [weight (kilogram) / height squared (metre
2
)]. Waist circumference (WC) was measured 
at the umbilicus by an experienced operator. 
 
Body Composition and Adipose Tissue Distribution 
Fat mass, abdominal fat mass and fat-free mass (FFM) were measured by dual-energy x-ray 
absorptiometry (DEXA) as described elsewhere (25). Single-slice Computer Tomography 
(CT) images were acquired at the level of L4–L5 intervertebral disc space and abdominal 
visceral fat (AVF) and abdominal subcutaneous fat cross-sectional areas (centimeters 
squared) were calculated as previously described (25).  
 
Hyperinsulinaemic euglycaemic Clamp 
IR was measured using the hyperinsulinaemic euglycaemic clamp technique as previously 
described (25, 26). Fasting venous blood samples were collected, centrifuged and stored for 
assessment of glucose, insulin, vitamin D, total cholesterol, high density lipoprotein (HDL), 
low density lipoprotein (LDL) and triglycerides as previously described (25). The glucose 
 8 
infusion rates (GIR) were calculated during the last 30 minutes of the hyperinsulinaemic 
euglycaemic clamp and expressed as glucose (mL) per hour per body surface area (m
2
) per 
minute. 
 
Plasma vitamin D 
Plasma vitamin D was determined using Liaison 25 OH vitamin D assay, a commercial direct 
competitive chemiluminescent immunoassay (CLIA) on a single assay. Vitamin D 
sufficiency is defined as plasma 25(OH)D concentration above 75 nmol/L. Vitamin D 
insufficiency refers to levels between 50 to 75 nmol/L and deficiency refers to levels less 
than 50 nmol/L (27).  
 
Metabolic syndrome 
Metabolic syndrome was determined using the World Health Organization (WHO) criteria 
which requires the presence of IR in addition to at least two other criteria (28). However, we 
did not have any information regarding urine albumin excretion, which is one of the 
additional criteria. 
 
Statistics 
 
All data were analysed using STATA software version 11.0 (StataCorp, TX). Data were 
assessed for normality and log transformed where appropriate and analysed using univariate 
analysis of variance (ANOVA). Post hoc analysis was conducted adjusting for multiple 
comparisons using the appropriate method (tukey) to adjust for possible type 1 errors. 
Continuous data are presented as mean ± SD or median (interquartile range) as appropriate. 
Correlation of vitamin D with IR, adiposity and cardiovascular risk factors was assessed 
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using Pearson or Spearman rank correlation where appropriate. Linear regression was used 
for assessment of factors associated with plasma vitamin D levels. Statistical significance was 
set at  level of p < 0.05.  
 
Results 
 
Results are presented for 76 subjects with samples available for analysis including vitamin D. 
22 lean women and 20 overweight women with PCOS and 19 lean and 15 overweight control 
women without PCOS were eligible at screening, completed the 3 month run-in phase with a 
steady diet, were compliant with withdrawal of relevant medications affecting glucose 
metabolism and completed data collection.  
 
PCOS vs. non-PCOS women: cardiometabolic status and vitamin D levels 
All baseline metabolic and clinical characteristics are presented in Tables 1 and 2. The 
overweight women with PCOS were younger than controls (29.8±5.5 years vs 35.1±4.1, 
p=0.004). There were no significant differences within the lean and obese groups with regard 
to blood pressure or lipid profile (Table 2). 
 
Overall, 71% (30/42) of women with PCOS were vitamin D deficient compared to 56% 
(19/34) of women without PCOS. Vitamin D levels were higher in overweight control 
women compared with overweight women with PCOS before (46.1±20.0 vs 31.6±11.3 
nmol/L respectively, p=0.01) and this persisted after adjustment for BMI and abdominal 
visceral fat (p=0.01). Vitamin D levels were similar between lean groups (p=0.97) (Table 2).  
 
Vitamin D and obesity 
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The lean and overweight experimental groups had similar adiposity within groups as 
determined by BMI and visceral abdominal fat content determined by CT (Table 2). Vitamin 
D was negatively associated with waist circumference (r= -0.41, p<0.001), BMI (r= -0.36, 
p=0.002), total fat mass (r= -0.39, p=0.001), % body fat (r= -0.37, p=0.002) and abdominal 
visceral fat (r= -0.41, p<0.001) before and after adjustment for age (all p<0.01). The 
correlation of vitamin D with adiposity measures between PCOS and non-PCOS groups are 
presented in Figure 1. 
 
Vitamin D and insulin resistance 
IR was not different between the lean PCOS and overweight controls as previously reported 
(16). As expected, IR was greatest in the overweight PCOS cohort and lowest in the lean 
PCOS cohort (Table 2). Vitamin D levels were positively associated with  
GIR (r=0.31, p=0.01). Vitamin D was associated with IR (GIR) on univariate regression (β 
coefficient 1.5, 95% CI 0.4 – 2.6, p=0.01), but was not associated with IR on multivariate 
regression when adjusted for PCOS status, age and % body fat. Both PCOS and % body fat 
were associated with IR in the multivariable regression model (β coefficient -66.3, 95% CI -
104.5 - -28.2, p=0.001 and β coefficient -3.7, 95% CI -5.6 - -1.8, p<0.001) (Table 3). To 
adjust for seasonal effects, the month of the year when clamp data were collected was 
included in the multivariable regression model, with no significant effect on results. There 
was a significant interaction between PCOS and % body fat for the outcome of IR (p=0.003). 
Further analysis by PCOS status revealed that vitamin D was associated with IR, independent 
of % body fat in the PCOS group (β coefficient 2.1, 95% CI 0.2 – 4.0, p=0.03). Vitamin D 
was not associated with IR in the non-PCOS group (Table 4). 
  
Vitamin D and CVD risk factors 
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There was a relationship between vitamin D and triglycerides after adjustment for age 
(p=0.01); however, this relationship was no longer significant after further adjustment for 
abdominal visceral fat (p=0.29). There was also a moderate correlation between vitamin D 
and high density lipoprotein (HDL) cholesterol before (r=0.38, p=0.001) and after adjustment 
for age and % body fat (p=0.001 and p=0.03 respectively). However, this relationship was no 
longer significant after further adjustment for abdominal visceral adiposity (p=0.23). There 
was no correlation with vitamin D and total cholesterol or LDL cholesterol levels. There was 
no correlation between vitamin D and systolic or diastolic blood pressure. 
 
Vitamin D and metabolic syndrome 
Ten of the 42 PCOS participants (23.8%) and three of the 33 control participants (9.1%) 
fulfilled the WHO diagnostic criteria for metabolic syndrome. Within the overweight cohort, 
ten of the 20 PCOS participants (50%) and two of the 14 control participants (14.3%) had 
metabolic syndrome. Vitamin D levels were lower in participants with both PCOS and 
metabolic syndrome compared to those with PCOS and without metabolic syndrome 
(27.4±9.8 vs 45.4±16.0 nmol/L respectively, p=0.002). A greater number of features of 
metabolic syndrome also correlated to lower vitamin D levels (Figure 2). 
 
Discussion 
 
In the present study, we report that despite similar adiposity, vitamin D levels were lower in 
overweight women with PCOS compared with overweight controls. We also showed using 
gold standard techniques, that vitamin D was correlated with IR and adiposity measures. A 
further novel finding from this study is that vitamin D was associated with IR in the PCOS 
group, but not in the non-PCOS group. With regard to cardiovascular risk factors, vitamin D 
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levels correlated with triglyceride levels and HDL cholesterol, but not total cholesterol, LDL 
levels or blood pressure. Finally, metabolic syndrome in PCOS was associated with lower 
levels of vitamin D compared to PCOS without metabolic syndrome and the number of 
features of metabolic syndrome was negatively progressively associated with lower levels of 
vitamin D overall. 
Vitamin D deficiency is common worldwide with estimated prevalence rates between 10 to 
60%, although the definition of vitamin D deficiency remains controversial (29). It is 
estimated that 67-85% of women with PCOS are vitamin D deficient with levels less than 20 
ng/mL (30), however reports are inconsistent. In the present study, we found that vitamin D 
was lower in overweight women with PCOS compared to overweight controls.  
It is unclear if the association between vitamin D and PCOS is primarily related to PCOS 
status per se or primarily related to greater visceral adiposity or to the IR more often seen in 
women with PCOS (31). Several PCOS studies have reported an inverse relationship between 
vitamin D and BMI and waist hip ratio; however few studies have utilized gold standard 
measures of adiposity from DEXA and CT derived body fat (20, 32-34). Our current study 
uses detailed body composition measures with both DEXA and CT and confirms existing 
literature. Vitamin D levels appear to be 27-56% lower in obese women with PCOS 
compared with non-obese women with PCOS (30). Women with PCOS who have hirsutism 
may be less inclined to sun exposure. In the present study, vitamin D was 36% lower in 
overweight women with PCOS compared to lean controls. Given that vitamin D is a fat 
soluble vitamin, it has been hypothesized that there may be lower bioavailability due to 
greater adipose tissue sequestration of vitamin D in obese states (35). It is also possible that 
there may be dietary differences or variance in sunlight exposure between obese and non-
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obese women as obese individuals are likely to be more sedentary hence spend more time 
indoors  (30), with more research needed to explore mechanisms of low vitamin D in obesity.  
It has been proposed that vitamin D deficiency may cause and worsen IR independent of 
adiposity (7, 36). The large, cross-sectional, nationally representative NHANES study 
(n=14,679) reported that IR determined by HOMA was inversely related to vitamin D after 
adjustment for confounders (8). Analysis of 808 non-diabetic participants of the Framingham 
Offspring Study found that plasma vitamin D levels were inversely associated with HOMA 
(7). Consistently, here we show that in women with PCOS, vitamin D is inversely associated 
with IR. Importantly, vitamin D supplementation (4000 IU/day) significantly improves IR 
(measured as HOMA) compared to placebo (11). A recent randomized double-blind placebo-
controlled study by Asemi et al was conducted in 104 overweight and obese vitamin D 
deficient women diagnosed with PCOS. Participants were divided into 4 groups and received 
calcium and/or vitamin D supplementation or placebo, with vitamin D and calcium 
decreasing serum insulin levels and improving IR (21). This raises the potential for vitmain D 
therapy to improve IR in PCOS with further research needed.  
IR is a key hormonal abnormality in women with PCOS; there is an extrinsic/obesity related 
IR and an intrinsic IR that is seen even in lean women with PCOS (16). It is unclear whether 
vitamin D deficiency and IR co-exist in PCOS women or whether the two are causally 
related. Several studies show an inverse association between vitamin D and IR in PCOS, 
using indirect measurements of IR (17-19). Muscogiuri et al (20) found that vitamin D 
deficiency was related to obesity and not IR using hyperinsulinaemic euglycaemic clamps 
and DEXA derived adiposity measures. However, only 37% of the 38 Italian women with 
PCOS were vitamin D deficient, potentially underestimating the relationship between vitamin 
D and IR. In addition, the Italian study did not have a control population. In the current study, 
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71% of the women with PCOS were vitamin D deficient and we also included women with 
more severe vitamin D deficiency. Gold standard hyperinsulinaemic euglycaemic clamps 
were used to measure IR with detailed body composition measures using both CT and DEXA 
and a control population of both lean and overweight women were studied. In the present 
study, we demonstrate that vitamin D was associated with IR independent of body fat 
percentage in the PCOS group, but not in the control group. A recent systematic review of 29 
studies found that on linear multivariate analysis, serum vitamin D was not an independent 
predictor of IR in women with PCOS (37). However the review included many studies where 
the mean BMI of participants with PCOS ranged from 25.1 to 28.0 kg/m
2
,
 
which may have 
underestimated the relationship. Our study, with an overall mean BMI of 28.9 kg/m
2
 in the 
PCOS group showed that vitamin D was independently associated with IR in women with 
PCOS. In addition, some the intervention studies detailed in the review included subjects who 
were only vitamin D insufficient but not deficient, had inadequate replacement of vitamin D 
and included studies with suboptimal study design.   
 
There are several meta-analyses that support an inverse association between vitamin D levels 
and the presence of major cardiovascular risk factors including hypertension, diabetes and 
metabolic syndrome, though the effect of vitamin D supplementation on cardiovascular risk 
factors is not clear (38). Prior studies have also shown relationships between low vitamin D 
levels and cardiovascular risk factors in PCOS. Vitamin D deficiency has been associated 
with systolic and diastolic blood pressure (33) and also with total cholesterol, triglycerides 
(33) and lower HDL cholesterol (34) levels. In the present study, we show associations 
between vitamin D and HDL cholesterol and triglycerides but not total or LDL cholesterol. 
The association between vitamin D and both HDL and triglycerides persists after adjusting 
for % body fat, but the association was no longer significant after adjusting also for 
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abdominal visceral fat. This suggests that abdominal visceral adiposity may be driving the 
relationship between vitamin D and HDL and triglycerides and highlights the importance of 
measuring visceral adiposity when studying vitamin D in PCOS.  
 
A large observational study of 206 women with PCOS revealed that women with both PCOS 
and metabolic syndrome had lower vitamin D levels than PCOS women without any features 
of metabolic syndrome (33). The systematic review by Krul-Poel et al (37) suggests that there 
is an inverse relationship between metabolic disturbances in women with PCOS and vitamin 
D levels. This is consistent with our study, where we show that having greater number of 
features of metabolic syndrome is negatively associated with vitamin D levels. A double 
blind placebo controlled randomized controlled trial (RCT) which studied the effect of 
vitamin D supplementation on cardiovascular risk factors found that there was no effect of 
vitamin D supplementation on IR in 50 women with PCOS (39). However, vitamin D 
supplementation in this trial did improve some cardiovascular risk factors including 
cholesterol, triglyceride and very low density lipoprotein (VLDL), but not HDL or LDL 
cholesterol (23). Larger RCTs are needed to further explore the impact of vitamin D 
supplementation on cardiovascular risk factors. 
 
Limitations of the study include a relatively small sample size. However, in order to detect 
the difference between lean and overweight women with PCOS, we required 19 participants 
in each group with a power 97% and alpha of 0.05.  Also, this is cross-sectional analysis and 
demonstrates association between variables. Both prospective studies and clinical trials 
supplementing vitamin D are needed to prove causality. Patients and controls are not age 
matched, yet this is adjusted for in the statistical analyses. Commercial immunoassays for 
vitamin D may produce variable results and tandem mass spectrometry is increasingly the 
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gold standard test that is used to measure vitamin D. The strengths of this study include the 
use of strict criteria to define PCOS and non-PCOS women and gold-standard techniques to 
measure IR and body composition.  
 
In conclusion, our data show that overweight PCOS women had lower vitamin D levels than 
overweight control women. Vitamin D correlated with IR and adiposity on gold standard 
measures including BMI, percentage body fat and abdominal visceral fat. Finally, vitamin D 
was associated with IR in the PCOS group independent of body fat percentage, but not in the 
non-PCOS group. This suggests that vitamin D may have a role in IR in PCOS; however 
further exploration in future mechanistic studies is needed. In addition, large-scale 
intervention studies are needed to explore the preventative potential of vitamin D 
supplementation on development of IR in PCOS. 
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Figure 1: Relationship of Vitamin D to adiposity measures and insulin resistance 
 
A  Relationship of vitamin D to body mass index (BMI) in PCOS group, R
2
 = 0.24, p=0.001  
B  Relationship of vitamin D to body mass index (BMI) in control group, R
2
 = 0.04, p=0.26  
C  Relationship of vitamin D to fat mass in PCOS group, R
2
 = 0.29, p<0.001 
D  Relationship of vitamin D to fat mass (BMI) in control group, R
2
 = 0.04, p=0.27  
E  Relationship of vitamin D to abdominal visceral fat in PCOS group, R
2
 = 0.29, p<0.001  
F  Relationship of vitamin D to abdominal visceral fat in control group, R
2
 = 0.09, p=0.09  
G  Relationship of vitamin D to glucose infusion rate (GIR) in PCOS group, R
2
 = 0.22, 
p=0.002  
H  Relationship of vitamin D to glucose infusion rate (GIR) in control group, R
2
 = 0.005, 
p=0.71  
 
 
  
 24 
Figure 2: Relationship between vitamin D and number of metabolic risk factors 
 
Mean plasma vitamin D level ± standard deviation
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